AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Company profile
Ticker
ABBV, ABBV-MM
Exchange
Website
CEO
Richard Gonzalez
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
AbbVie Aviation LLC • AbbVie Biopharmaceuticals LLC • AbbVie Bioresearch Center Inc. • AbbVie Biotech Ventures Inc. • AbbVie Biotherapeutics Inc. • AbbVie Domestic Holdings Inc. • AbbVie Endocrine Inc. • AbbVie Endocrinology Inc. • AbbVie Finance Corporation • AbbVie Finance LLC ...
IRS number
320375147
ABBV stock data
Latest filings (excl ownership)
PX14A6G
Letter to shareholders
26 Mar 24
ARS
2023 FY
Annual report to shareholders
18 Mar 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEF 14A
Definitive proxy
18 Mar 24
PRE 14A
Preliminary proxy
4 Mar 24
8-K
Other Events
26 Feb 24
424B5
Prospectus supplement for primary offering
26 Feb 24
FWP
Free writing prospectus
22 Feb 24
S-8
Registration of securities for employees
22 Feb 24
424B5
Prospectus supplement for primary offering
21 Feb 24
Transcripts
ABBV
Earnings call transcript
2023 Q4
2 Feb 24
ABBV
Earnings call transcript
2023 Q3
27 Oct 23
ABBV
Earnings call transcript
2023 Q2
27 Jul 23
ABBV
Earnings call transcript
2023 Q1
27 Apr 23
ABBV
Earnings call transcript
2022 Q4
9 Feb 23
ABBV
Earnings call transcript
2022 Q3
28 Oct 22
ABBV
Earnings call transcript
2022 Q2
29 Jul 22
ABBV
Earnings call transcript
2022 Q1
29 Apr 22
ABBV
Earnings call transcript
2021 Q4
2 Feb 22
ABBV
Earnings call transcript
2021 Q3
29 Oct 21
Latest ownership filings
4
Nicholas Donoghoe
22 Mar 24
144/A
Notice of proposed sale of securities (amended)
21 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Jeffrey Ryan Stewart
20 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
4
TIMOTHY J. RICHMOND
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Scott T Reents
1 Mar 24
4
Kevin K Buckbee
1 Mar 24
4
Robert A. Michael
1 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
49.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2718 |
Opened positions | 273 |
Closed positions | 515 |
Increased positions | 965 |
Reduced positions | 1180 |
13F shares | Current |
---|---|
Total value | 127.78 tn |
Total shares | 872.48 mm |
Total puts | 4.96 mm |
Total calls | 6.98 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 160.40 mm | $24.86 tn |
STT State Street | 78.20 mm | $12.12 tn |
JPM JPMorgan Chase & Co. | 51.82 mm | $8.03 tn |
Capital International Investors | 44.99 mm | $6.97 tn |
MS Morgan Stanley | 34.05 mm | $5.28 tn |
Capital Research Global Investors | 30.30 mm | $4.70 tn |
Charles Schwab Investment Management | 24.45 mm | $3.77 tn |
BK Bank Of New York Mellon | 22.10 mm | $3.43 tn |
NTRS Northern Trust | 20.94 mm | $3.24 tn |
LGEN Legal & General | 15.21 mm | $2.36 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 24 | Nicholas Donoghoe | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 176.3 | 21,082 | 3.72 mm | 55,903 |
18 Mar 24 | Jeffrey Ryan Stewart | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 178.69 | 27,740 | 4.96 mm | 60,941 |
18 Mar 24 | Jeffrey Ryan Stewart | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 179.03 | 5,099 | 912.87 k | 88,681 |
18 Mar 24 | Jeffrey Ryan Stewart | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 178.85 | 26,110 | 4.67 mm | 93,780 |
18 Mar 24 | Jeffrey Ryan Stewart | Common Stock, $0.01 par value | Option exercise | Acquire M | No | No | 61.36 | 26,110 | 1.60 mm | 119,890 |
18 Mar 24 | Jeffrey Ryan Stewart | Option Common Stock | Option exercise | Dispose M | No | No | 61.36 | 26,110 | 1.60 mm | 0 |
1 Mar 24 | Timothy J. Richmond | Common stock, $0.01 par value | Sell | Dispose S | No | Yes | 177.71 | 20,127 | 3.58 mm | 13,837 |
1 Mar 24 | Timothy J. Richmond | Common stock, $0.01 par value | Sell | Dispose S | No | Yes | 176.35 | 9,853 | 1.74 mm | 33,964 |
1 Mar 24 | Timothy J. Richmond | Common stock, $0.01 par value | Sell | Dispose S | No | Yes | 177.71 | 30,288 | 5.38 mm | 43,817 |
1 Mar 24 | Timothy J. Richmond | Common stock, $0.01 par value | Sell | Dispose S | No | Yes | 176.4 | 15,412 | 2.72 mm | 74,105 |
News
10 Health Care Stocks With Whale Alerts In Today's Session
28 Mar 24
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet Age-Related Macular Degeneration (AMD)
28 Mar 24
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
27 Mar 24
Barclays Maintains Overweight on AbbVie, Raises Price Target to $195
27 Mar 24
Assessing AbbVie's Performance Against Competitors In Biotechnology Industry
26 Mar 24
Press releases
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
27 Mar 24
NIMML Institute's TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie's Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13
25 Mar 24
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
25 Mar 24
U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
22 Mar 24